#CAR T cell immunotherapies

[ follow ]
#FDA investigation
WSJ
10 months ago
Health

FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells

CAR T cell therapies are being investigated by the FDA due to concerns that they may cause a type of white blood cell to become cancerous.
The risk of T cells becoming cancerous applies to all currently approved BCMA-directed and CD19-directed CAR T cell immunotherapies. [ more ]
WSJ
10 months ago
Health

FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells

CAR T cell therapies are being investigated by the FDA due to concerns that they may cause a type of white blood cell to become cancerous.
The risk of T cells becoming cancerous applies to all currently approved BCMA-directed and CD19-directed CAR T cell immunotherapies. [ more ]
WSJ
10 months ago
Health

FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells

CAR T cell therapies are being investigated by the FDA due to concerns that they may cause a type of white blood cell to become cancerous.
The risk of T cells becoming cancerous applies to all currently approved BCMA-directed and CD19-directed CAR T cell immunotherapies. [ more ]
WSJ
10 months ago
Health

FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells

CAR T cell therapies are being investigated by the FDA due to concerns that they may cause a type of white blood cell to become cancerous.
The risk of T cells becoming cancerous applies to all currently approved BCMA-directed and CD19-directed CAR T cell immunotherapies. [ more ]
moreFDA investigation
WSJ
10 months ago
Medicine

FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells

CAR T cell therapies are being investigated by the FDA due to concerns that they may cause a type of white blood cell to become cancerous.
The risk of T cells becoming cancerous applies to all currently approved BCMA-directed and CD19-directed CAR T cell immunotherapies. [ more ]
[ Load more ]